Intraoperative versus extended antimicrobial prophylaxis after gastric cancer surgery: a phase 3, open-label, randomised controlled, non-inferiority trial

被引:29
|
作者
Imamura, Hiroshi [2 ]
Kurokawa, Yukinori [1 ]
Tsujinaka, Toshimasa [3 ]
Inoue, Kentaro [4 ]
Kimura, Yutaka [5 ]
Iijima, Shohei [6 ]
Shimokawa, Toshio [7 ]
Furukawa, Hiroshi [2 ]
机构
[1] Osaka Univ, Grad Sch Med, Dept Surg Gastroenterol, Suita, Osaka, Japan
[2] Sakai Municipal Hosp, Dept Surg, Osaka, Japan
[3] Osaka Natl Hosp, Dept Surg, Osaka, Japan
[4] Kansai Med Coll, Dept Surg, Osaka, Japan
[5] NTT W Hosp, Dept Surg, Osaka, Japan
[6] Minoh City Hosp, Dept Surg, Osaka, Japan
[7] Univ Yamanashi, Grad Sch Med & Engn, Yamanashi, Japan
来源
LANCET INFECTIOUS DISEASES | 2012年 / 12卷 / 05期
关键词
SURGICAL-SITE INFECTION; ANTIBIOTIC-PROPHYLAXIS; NODAL DISSECTION; RISK-FACTORS; PREVENTION; D2; LYMPHADENECTOMY;
D O I
10.1016/S1473-3099(11)70370-X
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background Although evidence for the efficacy of postoperative antimicrobial prophylaxis is scarce, many patients routinely receive such treatment after major surgeries. We aimed to compare the incidence of surgical-site infections with intraoperative antimicrobial prophylaxis alone versus intraoperative plus postoperative administration. Methods We did a prospective, open-label, phase 3, randomised study at seven hospitals in Japan. Patients with gastric cancer that was potentially curable with a distal gastrectomy were randomly assigned (1:1) to receive either intraoperative antimicrobial prophylaxis alone (cefazolin 1 g before the surgical incision and every 3 h as intraoperative supplements) or extended antimicrobial prophylaxis (intraoperative administration plus cefazolin 1 g once after closure and twice daily for 2 postoperative days). Randomisation was stratified using Pocock and Simon's minimisation method for institution and American Society of Anesthesiologists scores, and Mersenne twister was used for random number generation. The primary endpoint was the incidence of surgical-site infections. We assessed non-inferiority of intraoperative therapy with a margin of 5%. Analysis was by intention-to-treat. During hospital stay, infection-control personnel assessed patients for infection, and the principal surgeons were required to check for surgical-site infections at outpatient clinics until 30 days after surgery. This study is registered with UMIN-CTR, UMIN000000631. Findings Between June 2,2005, and Dec 6,2007,355 patients were randomly assigned to receive either intraoperative antimicrobial prophylaxis alone (n=176) or extended antimicrobial prophylaxis (n=179). Eight patients (5%, 95% CI 2-9%) had surgical-site infections in the intraoperative group compared with 16 (9%, 5-14) in the extended group. The relative risk of surgical-site infections with intraoperative antimicrobial prophylaxis was 0.51 (0.22-1.16), which revealed statistically significant non-inferiority (p<0-0001). Interpretation Elimination of postoperative antimicrobial prophylaxis did not increase the incidence of surgical-site infections after a gastrectomy. Therefore, this treatment is not recommended after gastric cancer surgery. Funding Osaka Gastrointestinal Cancer Chemotherapy Study Group.
引用
收藏
页码:381 / 387
页数:7
相关论文
共 50 条
  • [1] Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial
    Jacewicz, Maciej
    Guenzel, Karsten
    Rud, Erik
    Sandbaek, Gunnar
    Magheli, Ahmed
    Busch, Jonas
    Hinz, Stefan
    Baco, Eduard
    LANCET INFECTIOUS DISEASES, 2022, 22 (10): : 1465 - 1471
  • [2] Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
    Cochereau, D.
    Lecuru, F.
    ONCOLOGIE, 2015, 17 (11-12) : 595 - 596
  • [3] Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
    Kehoe, Sean
    Hook, Jane
    Nankivell, Matthew
    Jayson, Gordon C.
    Kitchener, Henry
    Lopes, Tito
    Luesley, David
    Perren, Timothy
    Bannoo, Selina
    Mascarenhas, Monica
    Dobbs, Stephen
    Essapen, Sharadah
    Twigg, Jeremy
    Herod, Jonathan
    McCluggage, Glenn
    Parmar, Mahesh
    Swart, Ann-Marie
    LANCET, 2015, 386 (9990): : 249 - 257
  • [4] Antimicrobial prophylaxis for 1 day versus 3 days in liver cancer surgery: a randomized controlled non-inferiority trial
    Tadatoshi Takayama
    Osamu Aramaki
    Taro Shibata
    Masaaki Oka
    Toshiyuki Itamoto
    Mitsuo Shimada
    Shuji Isaji
    Takashi Kanematsu
    Shoji Kubo
    Masato Kusunoki
    Hidetaka Mochizuki
    Yoshinobu Sumiyama
    Surgery Today, 2019, 49 : 859 - 869
  • [5] Antimicrobial prophylaxis for 1 day versus 3 days in liver cancer surgery: a randomized controlled non-inferiority trial
    Takayama, Tadatoshi
    Aramaki, Osamu
    Shibata, Taro
    Oka, Masaaki
    Itamoto, Toshiyuki
    Shimada, Mitsuo
    Isaji, Shuji
    Kanematsu, Takashi
    Kubo, Shoji
    Kusunoki, Masato
    Mochizuki, Hidetaka
    Sumiyama, Yoshinobu
    SURGERY TODAY, 2019, 49 (10) : 859 - 869
  • [6] Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial
    Phillips, Richard O.
    Robert, Jerome
    Abass, Kabiru Mohamed
    Thompson, William
    Sarfo, Fred Stephen
    Wilson, Tuah
    Sarpong, Godfred
    Gateau, Thierry
    Chauty, Annick
    Omollo, Raymond
    Otieno, Michael Ochieng
    Egondi, Thaddaeus W.
    Ampadu, Edwin O.
    Agossadou, Didier
    Marion, Estelle
    Ganlonon, Line
    Wansbrough-Jones, Mark
    Grosset, Jacques
    Macdonald, John M.
    Treadwell, Terry
    Saunderson, Paul
    Paintsil, Albert
    Lehman, Linda
    Frimpong, Michael
    Sarpong, Nanaa Francisca
    Saizonou, Raoul
    Tiendrebeogo, Alexandre
    Ohene, Sally-Ann
    Stienstra, Ymkje
    Asiedu, Kingsley B.
    van der Werf, Tjip S.
    LANCET, 2020, 395 (10232): : 1259 - 1267
  • [7] Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial
    Jeong, Seung-Yong
    Park, Ji Won
    Nam, Byung Ho
    Kim, Sohee
    Kang, Sung-Bum
    Lim, Seok-Byung
    Choi, Hyo Seong
    Kim, Duck-Woo
    Chang, Hee Jin
    Kim, Dae Yong
    Jung, Kyung Hae
    Kim, Tae-You
    Kang, Gyeong Hoon
    Chie, Eui Kyu
    Kim, Sun Young
    Sohn, Dae Kyung
    Kim, Dae-Hyun
    Kim, Jae-Sung
    Lee, Hye Seung
    Kim, Jee Hyun
    Oh, Jae Hwan
    LANCET ONCOLOGY, 2014, 15 (07): : 767 - 774
  • [8] Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial
    Schilsky, Michael L.
    Czlonkowska, Anna
    Zuin, Massimo
    Cassiman, David
    Twardowschy, Carlos
    Poujois, Aurelia
    Gondim, Francisco De Assis A.
    Denk, Gerald
    Cury, Rubens G.
    Ott, Peter
    Moore, Joanna
    Ala, Aftab
    D'Inca, Renata
    Couchonnal-Bedoya, Eduardo
    D'Hollander, Koenraad
    Dubois, Nicolas
    Kamlin, C. Omar F.
    Weiss, Karl Heinz
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (12): : 1092 - 1102
  • [9] Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial
    Park, Ji Won
    Kang, Sung-Bum
    Hao, Jie
    Lim, Seok-Byung
    Choi, Hyo Seong
    Kim, Duck-Woo
    Chang, Hee Jin
    Kim, Dae Yong
    Jung, Kyung Hae
    Kim, Tae-You
    Kang, Gyeong Hoon
    Chie, Eui Kyu
    Kim, Sun Young
    Sohn, Dae Kyung
    Kim, Jae-Sung
    Lee, Hye Seung
    Kim, Jee Hyun
    Jeong, Seung-Yong
    Oh, Jae Hwan
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (07): : S69 - S77
  • [10] Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
    Parekh, Dipen J.
    Reis, Isildinha M.
    Castle, Erik P.
    Gonzalgo, Mark L.
    Woods, Michael E.
    Svatek, Robert S.
    Weizer, Alon Z.
    Konety, Badrinath R.
    Tollefson, Mathew
    Krupski, Tracey L.
    Smith, Norm D.
    Shabsigh, Ahmad
    Barocas, Daniel A.
    Quek, Marcus L.
    Dash, Atreya
    Kibel, Adam S.
    Shemanski, Lynn
    Pruthi, Raj S.
    Montgomery, Jeffrey Scott
    Weight, Christopher J.
    Sharp, David S.
    Chang, Sam S.
    Cookson, Michael S.
    Gupta, Gopal N.
    Gorbonos, Alex
    Uchio, Edward M.
    Skinner, Eila
    Venkatramani, Vivek
    Soodana-Prakash, Nachiketh
    Kendrick, Kerri
    Smith, Joseph A., Jr.
    Thompson, Ian M.
    LANCET, 2018, 391 (10139): : 2525 - 2536